Charles River Laboratories Provides Update on Planned Divestitures

About this update from Charles River Laboratories International, Inc.

[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":1245,"height":326,"url":"https://media.zenfs.com/en/business-wire.com/ce4fc02eb14c1edf6fb64e9d6a20f5b6"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/8mCvKTAtzazgC6AFALjiig--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTI1MTtjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/ce4fc02eb14c1edf6fb64e9d6a20f5b6","width":960,"height":251},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/EVZaxP0H4GLaGYn8fdYB0A--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD02Mjg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/ce4fc02eb14c1edf6fb64e9d6a20f5b6","width":1200,"height":314}},"lazy":false},{"type":"text","content":"– Announces Signing of Definitive Agreements to Divest the CDMO and Cell Solutions Businesses and Certain European Discovery Services Assets –","length":142,"tagName":"p","attribs":{}},{"type":"text","content":"– Updates 2026 Financial Guidance –","length":35,"tagName":"p","attribs":{}},{"type":"text","content":"WILMINGTON, Mass., February 25, 2026--(BUSINESS WIRE)--Charles River Laboratories International, Inc. (NYSE: CRL) today announced that it has signed definitive agreements to sell certain European Discovery Services assets as well as the CDMO and Cell Solutions businesses in separate transactions.","length":297,"tagName":"p"},{"type":"text","content":"James C. Foster, Chair, President and Chief Executive Officer, said, "We are pleased to announce these planned divestitures today to demonstrate our continued progress on the actions outlined as part of the comprehensive strategic review conducted last year. We have decided to divest these assets after carefully evaluating our core capabilities and determining those that will drive the most synergistic growth with our broader portfolio going forward. We believe these actions will refine and further strengthen our portfolio, and will also enhance shareholder value by executing on our plans to drive long-term growth, greater efficiency, and operational excellence."","length":681,"tagName":"p"},{"type":"text","content":"Planned Divestiture of CDMO and Cell Solutions Businesses","length":57,"tagName":"p"},{"type":"text","content":"Charles River has signed a definitive agreement to divest its CDMO and Cell Solutions businesses to GI Partner...

More updates from Charles River Laboratories International, Inc.